Leucovorin

Generic Name: Leucovorin

Brand Names: EnBrace HR, EnLyte, Lederle Leucovorin

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₃N_₇O_₇

CAS Number: 58-05-9

Unique Ingredient Identifier: Q573I9DVLP

Background: Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...

Indication: For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...

Associated Conditions: Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity

Associated Therapies: -

Clinical Trials

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin
Drug: leucovorin
Drug: methotrexate
Drug: vincristine

First Posted Date: 2003-01-27

Last Posted Date: 2012-11-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 56

Registration Number: NCT00041132

A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors

Phase 1

Completed

Conditions: Lymphoma
Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2006-07-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00001579

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00001449

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Breast Neoplasms

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00001498

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

First Posted Date: 2002-09-06

Last Posted Date: 2005-06-24

Lead Sponsor: Wellstat Therapeutics

Target Recruit Count: 24

Registration Number: NCT00044785

Locations: 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Neoplasms
Diarrhea

First Posted Date: 2002-06-27

Last Posted Date: 2016-12-01

Lead Sponsor: Celgene Corporation

Registration Number: NCT00040391

Locations: 🇺🇸
Research Center, Milwaukee, Wisconsin, United States

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

Phase 2

Terminated

Conditions: Neoplasm Metastasis
Colorectal Neoplasms

First Posted Date: 2002-05-17

Last Posted Date: 2008-09-29

Lead Sponsor: Pfizer

Target Recruit Count: 212

Registration Number: NCT00037180

Locations: 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States

Leucovorin for the Treatment of 5 q Minus Syndrome

Phase 2

Completed

Conditions: 5q Minus Syndrome
Myelodysplastic Syndrome

First Posted Date: 2000-03-23

Last Posted Date: 2008-03-04

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 14

Registration Number: NCT00004997

Locations: 🇺🇸
Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver

Phase 1

Completed

Conditions: Colorectal Neoplasm
Liver Neoplasm
Neoplasm Metastasis

First Posted Date: 1999-11-04

Last Posted Date: 2008-03-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00001576

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy